How did SABS's revenue and expenses trend in Q4 2024?

SAB Biotherapeutics (SABS) reported a revenue of $1.32 million and operating expenses of $11.39 million in Q4 2024, resulting in a net loss of $11.07 million. The gross profit margin was 100%, indicating that the company's cost of goods sold was zero or negligible compared to its revenue.

|code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code|
|---|---|---|---|---|---|---|
|SABS|SABS.O|SAB Biotherapeutics|20240101-2024|Grant|1322410|186|
|SABS|SABS.O|SAB Biotherapeutics|20240101-2024|Grant|1207712|186|
|SABS|SABS.O|SAB Biotherapeutics|20240101-2024|Grant|1207712|186|
|SABS|SABS.O|SAB Biotherapeutics|20240101-2024|Grant|944575|186|
|SABS|SABS.O|SAB Biotherapeutics|20240101-2024|Grant|944575|186|

|code|Ticker|Name|Date|Net Income YoY|Net Income|market_code|
|---|---|---|---|---|---|---|
|SABS|SABS.O|SAB Biotherapeutics|2024 Q1|31.658036231509612|-5025745|186|
|SABS|SABS.O|SAB Biotherapeutics|2024 Q2|-6.6062568105328285|-7335455|186|
|SABS|SABS.O|SAB Biotherapeutics|2024 Q3|-102.83745600283166|-1.034941E7|186|
|SABS|SABS.O|SAB Biotherapeutics|2024 Q4|50.14736338649528|-1.1394699E7|186|

|code|Ticker|Name|Date|Gross Profit Margin|Gross Profit Margin YoY|market_code|
|---|---|---|---|---|---|---|
|SABS|SABS.O|SAB Biotherapeutics|2024 Q1|100|0|186|
|SABS|SABS.O|SAB Biotherapeutics|2024 Q2|100|0|186|
|SABS|SABS.O|SAB Biotherapeutics|2024 Q3|100|0|186|
|SABS|SABS.O|SAB Biotherapeutics|2024 Q4|100|0|186|